Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease

Table 3 Comparison of time to symptom remission and hospital stay between the terlipressin treatment group and the conventional treatment group

	Terlipressin treatment group (n = 32)	Conventional treatment group (n = 98)	Z-value	P-value
Time to abdominal distension remission (d)	2.0 (1.0, 3.0)	4.0 (2.0, 6.0)	-4.851	< 0.001
Time to anal flatus (d)	1.0 (1.0, 2.0)	3.0 (2.0, 5.0)	-4.502	< 0.001
Hospital stay (d)	22.0 (15.3, 29.5)	22.0 (12.0, 32.3)	-0.014	0.989

Among patients with effective treatment, the number of days from the beginning of treatment to abdominal distension remission or the onset of anal flatus and feces passage was compared between the two groups. To be specific, the mean time to abdominal pain and bloating remission in the conventional treatment group was 4.0 (2.0, 6.0) days, while 2.0 (1.0, 3.0) days in the terlipressin treatment group. Additionally, the mean time to anal flatus and feces passage was 3.0 (2.0, 5.0) days in the conventional treatment group, compared with 1.0 (1.0,2.0) day in the terlipressin group. These differences were statistically significant (P < 0.05). The hospital length of stay in the terlipressin group was 22.0 (15.3, 29.5) days and 22.0 (12.0,32.3) days in the conventional treatment group. No statistical significance in the difference in hospital stay between the two groups of patients was shown (P > 0.05)

ISSN: 1471-230X